Xlife Sciences AG (XLS) - Total Assets
Based on the latest financial reports, Xlife Sciences AG (XLS) holds total assets worth CHF536.26 Million CHF (≈ $677.97 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Xlife Sciences AG (XLS) net assets for net asset value and shareholders' equity analysis.
Xlife Sciences AG - Total Assets Trend (2019–2024)
This chart illustrates how Xlife Sciences AG's total assets have evolved over time, based on quarterly financial data.
Xlife Sciences AG - Asset Composition Analysis
Current Asset Composition (December 2024)
Xlife Sciences AG's total assets of CHF536.26 Million consist of 2.6% current assets and 97.4% non-current assets.
| Asset Category | Amount (CHF) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CHF99.03K | 0.0% |
| Accounts Receivable | CHF8.46 Million | 1.6% |
| Inventory | CHF45.36K | 0.0% |
| Property, Plant & Equipment | CHF269.19K | 0.1% |
| Intangible Assets | CHF269.18 Million | 49.8% |
| Goodwill | CHF15.71K | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how Xlife Sciences AG's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see XLS market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Xlife Sciences AG's current assets represent 2.6% of total assets in 2024, a decrease from 3.3% in 2019.
- Cash Position: Cash and equivalents constituted 0.0% of total assets in 2024, up from 0.0% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 49.0% of total assets, an increase from 0.0% in 2019.
- Asset Diversification: The largest asset category is intangible assets at 49.8% of total assets.
Xlife Sciences AG Competitors by Total Assets
Key competitors of Xlife Sciences AG based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233
|
China | CN¥26.08 Billion |
|
Staidson Beijing Biopharma
SHE:300204
|
China | CN¥1.26 Billion |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.64 Billion |
|
Ardelyx Inc
NASDAQ:ARDX
|
USA | $486.17 Million |
|
Xiangxue Pharmaceutical
SHE:300147
|
China | CN¥7.36 Billion |
Xlife Sciences AG - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.08 | 2.70 | 5.78 |
| Quick Ratio | 1.07 | 2.70 | 5.78 |
| Cash Ratio | 0.00 | 0.01 | 2.21 |
| Working Capital | CHF956.73K | CHF11.30 Million | CHF2.62 Million |
Xlife Sciences AG - Advanced Valuation Insights
This section examines the relationship between Xlife Sciences AG's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.39 |
| Latest Market Cap to Assets Ratio | 0.23 |
| Asset Growth Rate (YoY) | 5.5% |
| Total Assets | CHF540.37 Million |
| Market Capitalization | $122.27 Million USD |
Valuation Analysis
Below Book Valuation: The market values Xlife Sciences AG's assets below their book value (0.23x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Xlife Sciences AG's assets grew by 5.5% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Xlife Sciences AG (2019–2024)
The table below shows the annual total assets of Xlife Sciences AG from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CHF540.37 Million ≈ $683.18 Million |
+5.54% |
| 2023-12-31 | CHF511.99 Million ≈ $647.30 Million |
+4.44% |
| 2022-12-31 | CHF490.23 Million ≈ $619.78 Million |
+2.12% |
| 2021-12-31 | CHF480.06 Million ≈ $606.93 Million |
+158.54% |
| 2020-12-31 | CHF185.68 Million ≈ $234.75 Million |
+20.56% |
| 2019-12-31 | CHF154.02 Million ≈ $194.72 Million |
-- |
About Xlife Sciences AG
Xlife Sciences AG focuses on the development and commercialization of research projects in the life sciences sector. The company's project covers technology platforms, biotechnology/therapies, medical technology, and artificial intelligence/digital health areas that focuses on identifying new therapeutic approaches and biomarkers for common diseases based on human genetic data. It also produces, … Read more